The biotech industry is facing an unprecedented intellectual property crisis. Recent high-profile lawsuits, including Bayer's case against Pfizer, Moderna, BioNTech, and J&J over mRNA vaccine technology, highlight the escalating legal risks. Biogen's $124 million royalty verdict and patent wars between Illumina, 10x Genomics, and Element Biosciences demonstrate that IP disputes can erase billions in enterprise value.

The core issue is that traditional annual IP reviews are obsolete in a landscape where preprints precede patents and platform technologies evolve monthly. Companies treating IP as a static asset are flying blind while burning capital. Continuous monitoring is essential because risk lives in subtle claim language drift, not just company-level competitor tracking.

Litigation is often a post-mortem, not an early warning. For companies working with CRISPR, gene therapy, synthetic biology, or AI-driven systems, IP drift is existential. Boards that already demand continuous security and compliance monitoring will soon require continuous IP monitoring to protect investments and ensure operational discipline.